Approximately 60 % of HER2-negative metastatic breast cancers express low levels of HER2, defined as an immunohistochemical (IHC) score of 1+ or an IHC score of 2+ with negative results on in situ hybridization (ISH) [7,8]. Here, ERBB2 is linked to breast cancer.